Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ...
Researchers are testing new therapies to treat celiac disease beyond a gluten-free diet, including immune tolerance drugs and ...
Ladies and gentlemen, thank you for standing by, and welcome to Aptar's 2026 First Quarter Results Conference Call. [Operator Instructions] Introducing today's conference call is Mrs. Mary Skafidas, ...
David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck KGaA, Darmstadt, Germany ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
If you experience fatigue, mood swings or insatiable cravings during the luteal phase, here are some ideas on how to eat to ...
Genomics, a science-led techbio company using large-scale genetic information to accelerate drug discovery and development and ...
"Overall, the quarter unfolded largely as we expected" and "underlying performance reflected a mixed operating environment, driven primarily by the anticipated emergency medicine destocking" ...
Syncromune is advancing SYNC-T Therapy SV-102 in the ongoing Phase 2 LEGION-100 study (NCT06533644), which is actively enrolling across multiple sites in the U.S. Please visit www.legion100trial.com ...
Various versions have been put forward regarding predictions of a post-capitalist future, including the possibility of a much ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results